To determine the incidence of Wnt pathway activation in patients with stage I NSCLC and its influence on lung cancer recurrence. Background: Despite resection, the 5-year recurrence with localized stage I nonsmall cell lung cancer (NSCLC) is 18.4%-24%. Aberrant Wnt signaling activation plays an important role in a wide variety of tumor types. However, there is not much known about the role the Wnt pathway plays in patients with stage I lung cancer. Methods: Tumor and normal lung tissues from 55 patients following resection for stage I NSCLC were subjected to glutathione S-transferase (GST) Ecadherin pulldown and immunoblot analysis to assess levels of uncomplexed β-catenin, a reliable measure of Wnt signaling activation. The β-catenin gene was also screened for oncogenic mutations in tumors with activated Wnt signaling. Cancer recurrence rates were correlated in a blinded manner in patients with Wnt pathway-positive and -negative tumors. Results: Tumors in 20 patients (36.4%) scored as Wnt positive, with only 1 exhibiting a β-catenin oncogenic mutation. Patients with Wnt-positive tumors experienced a significantly higher rate of overall cancer recurrence than those with Wnt-negative tumors (30.0% vs. 5.7%, P = 0.02), with 25.0% exhibiting distal tumor recurrence compared with 2.9% in the Wnt-negative group (P = 0.02). Conclusions: Wnt pathway activation occurred in a substantial fraction of Stage I NSCLCs, which was rarely due to mutations. Moreover, Wnt pathway activation was associated with a significantly higher rate of tumor recurrence. These findings suggest that Wnt pathway activation reflects a more aggressive tumor phenotype and identifies patients who may benefit from more aggressive therapy in addition to resection.
undergo surgical resection have the best 5-year survival rates. However, despite surgical resection, the 5-year recurrence in this group is 18.4%-24%, [4] [5] [6] and the 5-year survival rate is 58%-73%. 7 Adjuvant chemotherapy has been investigated to improve the survival of this group, but the results have been controversial. [8] [9] [10] The lack of better surgical cure for stage I patients and the apparent absence of any significant benefit from adjuvant chemotherapy to improve survival have led to efforts to evaluate this group of patients for prognostic factors that may help to guide future therapy. 11, 12 Investigations of the roles of specific cellular pathways in NSCLC initiation and progression have revealed the frequent occurrence of mutations involving p53, K-ras, and epidermal growth factor receptor (EGFR). [13] [14] [15] A number of studies have suggested that mutations in these genes are associated with advanced disease stage and poor prognosis. However, such findings have not been consistent. 11, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Wnt signaling plays critical roles in normal development and in postnatal tissue homeostasis through maintenance of stem/progenitor cells. 25 Moreover, this pathway appears to regulate cell fate and differentiation in early lung development. 26 A critical downstream effector in the canonical Wnt pathway is β-catenin, which is normally bound to E-cadherin at the inner surface of the cell membrane. A degradation complex composed of glycogen synthase kinase-3β (GSK-3β), adenomatous polyposis coli (APC), and axin phosphorylates and processes unbound β-catenin for proteosomal degradation. Triggering of their cell surface receptors by secreted Wnt canonical family members leads to inhibition of the degradation complex, resulting in β-catenin accumulation and translocation to the nucleus, where it participates as a transcription factor with T-cell factor /lymphoid enhancer factor (TCF/LEF) transcription factors in the activation of target genes. 25, 27 Aberrant Wnt signaling activation resulting from genetic alterations in intracellular components of this pathway plays an important role in the development of a variety of tumor types. 28 Inactivating mutations of the APC gene are frequently observed in colorectal cancers, whereas mutations or in-frame deletions of exon 3 of the β-catenin gene, which prevent β-catenin phosphorylation and proteosome targeting, have been observed in more than 90% of colon cancers and at lower frequencies in liver, endometrium, ovary, prostate, and stomach carcinomas. [29] [30] [31] [32] [33] [34] These genetic alterations result in constitutive activation of TCF transcription through the stabilization of β-catenin and the inappropriate activation of TCF target genes believed to be critical in tumorigenesis. More recently, Wnt canonical pathway activation has been observed in a substantial fraction of human breast, ovarian, and NSCLC cell lines. Levels of Wnt activation as measured by uncomplexed β-catenin or TCF transcriptional activation ranged from 5-fold to more than 100-fold higher than in normal or other tumor cells of the same tissue types. [35] [36] [37] [38] [39] [40] An autocrine mechanism involving overexpression of Wnt ligands and/or receptors, rather than APC or β-catenin mutations, was identified as the most frequent cause of pathway activation. 39 Evidence that Wnt pathway downregulation caused specific inhibition of the proliferation of such tumor cells argues that Wnt signaling contributes importantly to the malignant phenotype. 38, 39, 41 Thus, concerted efforts are underway to identify small molecule inhibitors and other approaches with which to therapeutically target this activated pathway in tumors. 42 There is only limited evidence concerning the prevalence and clinical significance of Wnt pathway activation in tumors of NSCLC patients. 40, 43 These studies have relied on the use of immunostaining for β-catenin to assess Wnt pathway activity in NSCLC tissues and have led to conflicting findings concerning both prevalence and prognostic implications. We developed a biochemical approach to identify Wnt activation in primary NSCLC by comparison of uncomplexed β-catenin levels in tumor and normal lung tissues of the same patient and utilized this methodology to determine the frequency of Wnt pathway activation in stage I NSCLC and its influence on lung cancer recurrence.
METHODS Patients
NSCLC tumor and normal tissues were obtained from the Tisch Cancer Institute Biorepository, The Mount Sinai Medical Center. We selected patients who underwent resection for stage I NSCLC from June 2006 to June 2008. All patients in this study were determined to be stage I based on pathological staging, in which they underwent lymph node sampling including N1, upper, and lower mediastinal nodes. Although pathological reports did not consistently specify the station numbers for N1 nodes being evaluated, each specimen had multiple N1 lymph nodes examined by the pathologist. Patients underwent preoperative staging with CT and PET scans and were deemed to be stage I by these criteria as well. Tissue specimens were linked to each patient through a unique number assigned to each patient. Paired samples of tumor and normal lung were obtained from each consented patient. None of the patients in the study had been given chemotherapy or radiation before surgery. We used prospectively collected data linked to this tissue bank to obtain information on patient demographics, comorbidities, operative course, pathological staging, and postoperative course. Inpatient and outpatient charts were reviewed, and patients were also contacted for additional follow-up information. Pathological staging was performed in accordance with the guidelines set forth by the American Joint Committee on Cancer (AJCC). 44 The study was reviewed and approved by Mount Sinai's Institutional Review Board.
Tissue Samples
Tissues were immersed in optimal cutting temperature (OCT) compound and frozen at -70 • C. Hematoxylin and eosin (H&E)stained sections were reviewed by a pulmonary pathologist to confirm the diagnosis and quality of tissue, and 20-μm-thick cryosections were obtained for analysis of tumor sections exhibiting the presence of more than 50% of tumor cells. Matched normal lung tissue scored as containing 100% normal cells from each patient served as a negative control.
Protein Extraction and Western Blot Analysis
Cryosections were homogenized in a lysis buffer as previously described 45 using mortar and pestle. Uncomplexed β-catenin was measured by a capture assay using glutathione S-transferase (GST) fused to the β-catenin-binding domain of E-cadherin synthesized in Escherichia coli. 45 The immunoblot analysis of uncomplexed and total β-catenin was performed as previously described 45 using mouse β-catenin primary antibody (BD Pharmingen, San Jose, CA). Antimouse immunoglobulin G (IgG) secondary antibody conjugated to Alexa Fluor 680 was purchased from GE Healthcare Life Sciences (Buckinghamshire, UK). Quantification of immunoreactivity was done using the Licor Odyssey Imaging System (LI-COR, Lincoln, NE). For each set of paired normal and tumor samples, the capture assay and a Western blot analysis were performed at least twice on consecutive sections of the same tissue with Wnt-activated H23 NSCLC cells and Wnt-negative 293T cells, respectively, serving as positive and negative controls.
Quantification of TCF-Mediated Luciferase Reporter Activity
293T cells were infected with TOP-luciferase and Renilla luciferase (Renilla-luciferin 2-monooxygenase-an enzyme isolated from Renilla reniformis, the sea pansy) as previously described. 39 Cells were plated in 10-cm plates at 1 × 10 6 cells/plate and treated 24 hours later with increasing concentrations of Wnt3a-or controlconditioned medium for 48 hours. Cells were then trypsinized, washed, and resuspended in 10 times the cell volume before lysis and processing for luciferase reporter assay using the dual luciferase reporter kit (Promega, Madison, WI) according to the manufacturer's protocol. Luciferase reporter activity was calculated by dividing the activity of TOP-luciferase by that of Renilla luciferase. The rest of the cells were processed for the immunoblot analysis of uncomplexed and total β-catenin as previously described. 45 
Sequencing of CTNNB1 Exon 3
Genomic DNA was extracted from NSCLC tissue specimens using the DNeasy extraction kit (Qiagene, Germantown, MD), and PCR-amplified primers flanking β-catenin (CTNNB1) exon 3 (forward 5'-TTGATGGAGTTGGACATG; reverse 5'-CAGCTACTTGTTCTTGAG). This region of the β-catenin gene corresponds to the N-terminal phosphorylation domain that contains the sites of known β-catenin mutations in tumors. 46 Gel-purified PCR fragments were sequenced by the Mount Sinai Genomics Core Facility.
Statistical Analysis
The clinical characteristics of patients with Wnt-positive and -negative NSCLCs were compared using the Student t test, the Wilcoxon test, or the χ 2 test, as appropriate. Disease-free survival of patients with Wnt-positive and -negative tumors was determined by the Kaplan-Meier method. Disease-free survival was defined as the time from surgery to the first diagnosis of local, regional, or distal disease recurrence, or until the last follow-up. We used the Cox proportional hazards regression analysis to assess whether Wnt status was associated with disease-free survival after controlling for other prognostic factors. The SAS 9.0 statistical package (SAS Institute, Cary, NC) was used for all statistical analyses. A 2-tailed P-value of less than 0.05 was considered significant.
RESULTS
To validate the capture assay for determination of uncomplexed β-catenin levels in cells or tissues as a surrogate for detection of Wnt activation, we exposed 293T cells to increasing Wnt3a concentration and compared the resulting increase in uncomplexed β-catenin as measured by the capture assay with levels of TCF transcription activation using a reporter for TCF signaling. Figure 1A shows that uncomplexed β-catenin levels increased as a function of increasing Wnt concentration, whereas total β-catenin levels were little affected. Moreover, the increased levels of uncomplexed β-catenin correlated well, but with a less dynamic range compared with the increasing levels observed in TCF reporter activity (Fig. 1B) -a sensitive marker for Wnt pathway activity in living cells. 39 We next applied the capture assay to the analysis of Wnt signaling in paired stage I NSCLC and normal lung tissues. Figure  1C shows results with matched tumor and normal lung tissue samples from representative stage I NSCLC patients. H23, a Wnt 293T cells transduced with TOP-luciferase and Renilla luciferase lentiviruses were treated for 48 hours with increasing concentration of Wnt3a-conditioned medium. A, Glutathione S-transferase (GST)-E cadherin capture assay as described in the "Methods" was performed on the treated cells. Total cell lysates (20 μg) and the GST-E-cadherin precipitates from 800 μg of cell lysate were subjected to an immunoblot analysis with an mAb directed against β-catenin. B, TCF reporter luciferase activity was performed on 1:10 of cell volume from the same Wnt3a-conditioned medium treated cells as described in the "Methods." Luciferase reporter activity was calculated by dividing the TOP-luciferase by Renilla luciferase (RL). C, β-catenin capture assay performed with 2 representative human paired NSCLC and normal lung tissues in 2 independent experiments. Total cell lysates (800 μg) were subjected to GST-E cadherin capture assay as described in Figure 1A . T denotes tumor specimen and N denotes normal lung tissue from the same patient. H23, a Wnt autocrine-activated NSCLC line, and 293T, an immortalized human embryonic kidney line, were used as positive and negative controls, respectively.
autocrine-activated NSCLC cell line, and 293T, a Wnt-negative immortalized human embryonic kidney line, served as positive and negative controls, respectively, in this analysis. 39 It can be readily observed in independent tests that tumor tissue from patient 9 showed increased uncomplexed β-catenin levels when compared with normal lung tissue from the same patient. In contrast, tumor and normal tissue of patient 19 showed no differences in uncomplexed β-catenin expression under the same conditions. For each tumor and normal tissue pair, we also analyzed total β-catenin and actin levels as internal controls for the amount of protein utilized in the capture assay. Results of the replicate analysis of the same samples were consistent (Figs. 1C, 2 , and data not shown).
We tested Wnt activation by this approach in paired tumor and normal lung tissue samples from 55 stage 1 NSCLC patients. For each paired sample, 2 different observers scored results in the absence of any knowledge of clinical data. Using this approach, tumors from 20 patients (36.4%) exhibited elevated levels of uncomplexed β-catenin. Mutations at specific serine and threonine residues within the Nterminal domain of β-catenin inhibit its phosphorylation-dependent degradation. 46 To investigate the presence of mutations in this region, we performed a sequence analysis on tumors that scored positive in the capture assay. Only 1 (5.0%) Wnt pathway-activated tumor specimen contained a β-catenin mutation. This tumor exhibited a TCT-to-TGT mutation, changing serine to cysteine in exon 3-a common site for β-catenin oncogenic activation. 46, 47 Thus, the great majority of positive tumors were likely due to Wnt pathway upregula-tion by an autocrine mechanism previously identified in NSCLC cell lines. 39 To analyze the relationship of elevated Wnt activity to lung cancer recurrence, patients were divided into Wnt-positive (+Wnt) and Wnt-negative (-Wnt) groups before decoding of the clinical data relevant to each sample. Figure 2 shows that 6 out of the 8 tumors from patients showing recurrence scored as Wnt-activated. Quantitative densitometry confirmed that the ratio of uncomplexed β-catenin levels to total β-catenin levels in tumor tissue as compared with normal lung tissue from the same patient was greater than 2.5 for each tumor scored as +Wnt, whereas the ratio was 1.0 or less for the tumors scored as -Wnt ( Supplementary Figure 1 Patient and tumor characteristics for +Wnt and -Wnt groups are summarized in Tables 1 and 2 , respectively. Overall, the mean age of the patients was 67.9 years, and the median smoking history was 40 pack-years. The majority had adenocarcinomas with a median tumor size of 2.0 cm. The 2 groups were statistically similar in their major characteristics, including age, sex, tumor size, and type of resection ( Table 1 ). The mean follow-up length was 24.6 and 21.6 months in the +Wnt and -Wnt group, respectively. The postoperative recurrence rate was 30.0% (n = 6) in the +Wnt group and 5.7% (n = 2) in the -Wnt group ( Table 2 ; P = 0.02). Disease-free survival was significantly better for the -Wnt group compared with the +Wnt group (P = 0.029; Fig. 3 ). An analysis of recurrences revealed that patients in the +Wnt group also had a significantly higher risk of FIGURE 2. Wnt pathway activation as measured by the β-catenin capture assay in NSCLCs from patients who developed recurrence. T denotes tumor specimen and N denotes normal lung tissue from the same patient. H23, a Wnt autocrine-activated NSCLC line, and 293T, an immortalized human embryonic kidney line, were used as positive and negative controls, respectively. distal recurrence compared with those in the -Wnt group (25.0% vs. 2.9%, P = 0.02). The data on site of tumor recurrence are presented in Table 3 . Multiple regression analysis revealed that Wnt pathway activation was the only independent risk factor for recurrence (P = 0.04) after adjusting for age, sex, type of resection, and stage. A minority of NSCLCs were squamous cell carcinomas, and Wnt activation in these tumors occurred at a lower frequency (2 out of 10 tumors) than was observed for adenocarcinomas (18 out of 43 tumors), as indicated in Table 2 . We then performed a statistical analysis of the recurrence frequency in these patients with Wnt-positive versus Wnt-negative adenocarcinomas. The results also showed a higher rate of recurrence in patients with Wnt-positive versus Wnt-negative adenocarcinomas (33.3% vs. 8.0%, P = 0.05).
TABLE 1. Demographic and Clinical Patient Characteristics

DISCUSSION
The present study analyzed the frequency of Wnt pathway activation in stage I NSCLC, the mechanisms involved, and the re- lationship of Wnt pathway activation to disease-free survival. This is the first study to utilize uncomplexed β-catenin levels as a means to measure Wnt pathway activation in this way. This biochemical assay is only semiquantitative but improves on immunostaining, which cannot discriminate between uncomplexed (active) and complexed β-catenin (inactive) and, thus, cannot quantify Wnt pathway activation. When we quantified the immunoreactivity of uncomplexed β-catenin in tissue lysates using the Licor Odyssey Imaging System, the densitometric analysis revealed that the ratio of uncomplexed β-catenin levels to total β-catenin levels in tumor tissue as compared with normal lung tissue of the same patient was greater than 2.5 for tumors scored as +Wnt, whereas the ratio was 1.0 or less for those tumors scored as -Wnt. Using this approach, Wnt pathway activation occurred frequently in patients with stage I NSCLC and was found to be potentially useful as a prognostic factor for cancer recurrence. For surgically resected stage I NSCLC, the 5-year recurrence is 18.4%-24%. [4] [5] [6] To date, there has not been consistent evidence indicating a benefit of chemotherapy after surgery in patients with early-stage NSCLC. Because of heterogeneity in recurrence rates among patients within the same stage, a reliable tumor molecular or genetic marker that predicts those patients likely to develop recurrent disease might identify a subset that would benefit from adjuvant chemotherapy. Several studies based on microarray technology have been performed to determine genetic profiles predictive of survival in NSCLC and to develop genomic approaches for stratifying risk. [48] [49] [50] However, the identified survival-related genes have lacked consistency among these studies. This may be due to differences in microarray technique, samples analyzed, and/or statistical methods applied. Also, mRNA expression cannot always indicate which proteins are expressed or how their activities may be modulated.
Mutations of K-ras, EGFR, and p53 are frequently observed in NSCLC and have been analyzed as predictive markers. [13] [14] [15] Some studies have suggested that mutations which activate K-ras or EGFR and inactivate p53 are associated with advanced disease stage and poor prognosis in NSCLC. [16] [17] [18] [19] [20] However, such findings have not been consistent. 11, 14, 15, [21] [22] [23] [24] Moreover, most of these studies have involved analysis of heterogeneous groups of patients across different stages of disease.
Studies evaluating the role of these pathways as prognostic markers in early-stage NSCLC have also resulted in conflicting findings. 11, 18, 21 Silini and colleagues reported that K-ras mutation has an adverse effect on survival in patients with stage I lung adenocarcinoma 51 However, other studies showed no statistically significant difference in overall or cancer-specific survival in patients with stage I NSCLC. 52, 53 Similarly, conflicting outcomes have been reported on the roles of EGFR and p53 as potential prognostic markers in early-stage NSCLC. 11, 15, 24, 54 Whereas K-ras mutations tend to occur most commonly in the adenocarcinomas of the lung in smokers, EGFR mutations appear to target adenocarcinomas arising in individuals who have never smoked. 55, 56 These findings suggest that K-ras and EGFR mutations may each exclude substantial numbers of patients. The problems associated with the use of p53 mutations as a prognostic marker are due to the heterogeneity in methodology for detecting the presence of p53 mutations, which have been reported in terms of both gene mutations and detection of protein expression. Also, a large spectrum of "hot spots" makes mutational analysis of p53 gene difficult in the clinical testing.
There is a growing body of evidence for activation of Wnt pathway in NSCLC. 39, 40, 43 Efforts to detect evidence of Wnt pathway activation in lung tumor tissues by immunostaining revealed different patterns of β-catenin expression, including membranous, membranous-cytoplasmic, and cytoplasmic-nuclear, at frequencies that were difficult to reconcile with the lack of β-catenin mutations detected in the same large series. 57 The mechanism responsible for a much higher frequency of Wnt pathway activation in NSCLC than accounted for by pathway activating mutations in known intracellular components, β-catenin, or APC 58, 59 derives from demonstration of autocrine mechanism in as many as 40%-50% of NSCLC cell lines. 39 It is worth nothing that treatment of such tumor cells with Wnt antagonists, dickkopf-1 (DKK1) or frizzled-related protein (FRP), which act at the cell surface to inhibit Wnt-receptor interaction, resulted in downregulation of activated Wnt signaling associated with inhibition of NSCLC proliferation and acquisition of a more differentiated phenotype. 39 In our present study, primary NSCLCs showed a high prevalence of Wnt pathway activation, as measured by elevated levels of uncomplexed β-catenin, with 36.4% exhibiting increases compared with matched normal lung tissues. Nevertheless, only 1 patient out of 20 with activated Wnt signaling exhibited a β-catenin oncogenic mutation, consistent with previous findings that such mutations are rare events in NSCLC. 39, 57, 59 The high prevalence of Wnt pathway activation in NSCLC tissues analyzed by us strongly supports the conclusion that a Wnt autocrine mechanism is responsible in the large majority of Wnt-activated primary NSCLCs.
Using immunostaining approaches, previous studies indicated that increased expression of β-catenin predicted a favorable prognosis in patients with NSCLC after resection. [60] [61] [62] Hommura and colleagues reported a trend toward improved survival in patients with tumors having higher β-catenin expression. A multivariate analysis also showed that high β-catenin expression was a significant and independent favorable prognostic factor (P = 0.007). 60 Another report indicated that reduced β-catenin expression in surgically treated NSCLC was associated with lymph node metastasis and an unfavorable prognosis. 61 In contrast, other studies have suggested that overexpression of the Wnt pathway is associated with poor tumor differentiation and tumor progression. 40, 43 Immunostaining for Wnt 1 ligand expression led to the conclusion that Wnt1-positive status was a significant prognostic factor for recurrence in NSCLC patients (P = 0.013). Wnt1 expression was also found to correlate with the expression of reported Wnt pathway targets, including c-Myc, vascular endothelial growth factor-A (VEGF-A), and matrix metalloproteinase-7 (MMP-7). 43 All of these studies evaluated the level of the Wnt pathway activity using immunohistochemical staining for β-catenin protein, which is not quantitative and may be confounded by the presence of inactive, complexed β-catenin.
In the present study, those patients identified as having increased Wnt pathway activity by the capture assay exhibited a higher rate of recurrence than those whose tumors showed no Wnt activation. Moreover, the pattern of recurrence in the +Wnt group favored distal metastasis, with 5 patients (25.0%) in this group developing metastases distally compared with 1 patient (2.9%) in the -Wnt group ( Table 4 ). These results are consistent with those of a study by Nguyen and colleagues, who analyzed the role of Wnt pathway in determining distal NSCLC metastasis to the brain and bones. They found that Wnt pathway activation, through homeobox protein (Hox-B9) and LEF1 target genes, was associated with metastasis to multiple organs in mouse models and humans. Also, reduction in Wnt activity attenuated the ability to form brain or bone metastasis in a mouse model. 63 There are some limitations in our study. Although our analysis showed that Wnt pathway activation significantly increases the risk of recurrence after resection of stage I NSCLC, the sample size used in the study was relatively small. Thus, larger studies will be necessary to confirm our observations. Also, follow-up of the patients potentially was not long enough to detect all recurrences despite the fact that the mean follow-up time of around 2 years should capture most recurrences. In fact, new localized malignant lesions more than 2 years after resection of early-stage lung cancers are more likely due to new primary malignancies than due to recurrences. 4, 64 Adjuvant chemotherapy has been shown to benefit patients with stage II-III NSCLC. However, the benefit for stage IB patients is controversial. [8] [9] [10] The stage IA patient group does not appear to benefit from adjuvant therapy after surgical resection. 65 Our study is the first utilizing a quantitative means of identifying Wnt-activated primary tumors to measure the level of Wnt pathway activity and correlate it with clinical outcomes. An increased level of Wnt pathway activation was associated with a statistically significant increased risk of tumor recurrence after surgical resection. Thus, Wnt pathway activation may have an important role in guiding adjuvant therapy in stage I patients. Investigating potential benefits of adjuvant chemotherapy in such patients could be an important step in efforts to improve outcomes of stage I NSCLC patients.
